Literature DB >> 25177378

Diagnostic Value of (68)Ga-DOTATATE PET/CT in Liver Metastases of Neuroendocrine Tumours of Unknown Origin.

Teik Hin Tan1, Boon Nang Lee1, Siti Zarina Amir Hassan1.   

Abstract

PURPOSE: In neuroendocrine liver metastases of unknown primary, a multimodality approach is usually adopted and consists of transabdominal ultrasound, endoscopic ultrasound (EUS), computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine techniques, endoscopy and exploratory surgery. The purpose of the study is to evaluate the diagnostic value of (68)Ga-DOTATATE positron emission tomography (PET)/CT as part of a multimodality approach in neuroendocrine liver metastases of unknown primary.
MATERIALS AND METHODS: Six patients (M:F = 5:1, age range 28-56 years) with immunohistochemically proven neuroendocrine liver metastases but inconclusive initial CT work-up were retrospectively analysed. Clinical finding, histopathology, comparative imaging and follow-up were used to validate the results when ethically justified.
RESULTS: (68)Ga-DOTATATE PET/CT identified the primary tumour in five out of six (83.3 %) patients: pancreas (n = 4) and stomach (n = 1). Out of three patients with indeterminate primary on initial CT, two patients were confirmed by (68)Ga-DOTATATE PET/CT. Absence of uptake in indeterminate primary of one patient was later confirmed negative by histopathology. In another three patients with undetected primary on initial CT, primary site was demonstrated in all patients with unsuspected metastases in two patients on (68)Ga-DOTATATE PET/ CT. No further work-up was done to confirm the primary in patients with distant metastases. Change of management was observed in three out of six (50 %) patients.
CONCLUSION: Our small study indicates that (68)Ga-DOTATATE PET/CT is a promising diagnostic option in the multimodality approach to neuroendocrine liver metastases of unknown primary origin.

Entities:  

Keywords:  68Ga-DOTATATE; Liver metastases; Neuroendocrine tumour; Unknown primary

Year:  2013        PMID: 25177378      PMCID: PMC4145102          DOI: 10.1007/s13139-013-0258-9

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  26 in total

1.  68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

Authors:  Yodphat Krausz; Nanette Freedman; Rina Rubinstein; Efraim Lavie; Marina Orevi; Sagi Tshori; Asher Salmon; Benjamin Glaser; Roland Chisin; Eyal Mishani; David J Gross
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

2.  ⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin.

Authors:  Niraj Naswa; Punit Sharma; Abhishek Kumar; Ramya Soundararajan; Rakesh Kumar; Arun Malhotra; Ariachery C Ammini; Chandrashekhar Bal
Journal:  Clin Nucl Med       Date:  2012-03       Impact factor: 7.794

3.  Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

Authors:  Matthias Miederer; Stefan Seidl; Andreas Buck; Klemens Scheidhauer; Hans-Jürgen Wester; Markus Schwaiger; Aurel Perren
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-20       Impact factor: 9.236

Review 4.  Standard imaging techniques for neuroendocrine tumors.

Authors:  David L Bushnell; Richard P Baum
Journal:  Endocrinol Metab Clin North Am       Date:  2011-03       Impact factor: 4.741

Review 5.  Pathology - grading and staging of GEP-NETs.

Authors:  Paola Capelli; Matteo Fassan; Aldo Scarpa
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

6.  Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment.

Authors:  S Froidevaux; E Hintermann; M Török; H R Mäcke; C Beglinger; A N Eberle
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

7.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

8.  Neuroendocrine liver metastases: contributions of endoscopy and surgery to primary tumor search.

Authors:  Herwig Cerwenka
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

Review 9.  Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications.

Authors:  J C Reubi; J Laissue; E Krenning; S W Lamberts
Journal:  J Steroid Biochem Mol Biol       Date:  1992-09       Impact factor: 4.292

10.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

View more
  8 in total

Review 1.  Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?

Authors:  Prasanna Santhanam; Sangeeta Chandramahanti; Alexander Kroiss; Run Yu; Philippe Ruszniewski; Rakesh Kumar; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-13       Impact factor: 9.236

2.  Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis.

Authors:  Sara De Dosso; Giorgio Treglia; Mariarosa Pascale; Adriana Tamburello; Prasanna Santhanam; Alexander S Kroiss; Ricardo Pereira Mestre; Piercarlo Saletti; Luca Giovanella
Journal:  Endocrine       Date:  2019-04-19       Impact factor: 3.633

3.  Comparison of Diagnostic Sensitivity and Quantitative Indices Between (68)Ga-DOTATOC PET/CT and (111)In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report.

Authors:  Inki Lee; Jin Chul Paeng; Soo Jin Lee; Chan Soo Shin; Jin-Young Jang; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Nucl Med Mol Imaging       Date:  2015-08-26

4.  Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group.

Authors:  Rachel P Riechelmann; Rui F Weschenfelder; Frederico P Costa; Aline Chaves Andrade; Alessandro Bersch Osvaldt; Ana Rosa P Quidute; Allan Dos Santos; Ana Amélia O Hoff; Brenda Gumz; Carlos Buchpiguel; Bruno S Vilhena Pereira; Delmar Muniz Lourenço Junior; Duilio Reis da Rocha Filho; Eduardo Antunes Fonseca; Eduardo Linhares Riello Mello; Fabio Ferrari Makdissi; Fabio Luiz Waechter; Francisco Cesar Carnevale; George B Coura-Filho; Gustavo Andrade de Paulo; Gustavo Colagiovanni Girotto; João Evangelista Bezerra Neto; João Glasberg; Jose Claudio Casali-da-Rocha; Juliana Florinda M Rego; Luciana Rodrigues de Meirelles; Ludhmila Hajjar; Marcos Menezes; Marcello D Bronstein; Marcelo Tatit Sapienza; Maria Candida Barisson Villares Fragoso; Maria Adelaide Albergaria Pereira; Milton Barros; Nora Manoukian Forones; Paulo Cezar Galvão do Amaral; Raphael Salles Scortegagna de Medeiros; Raphael L C Araujo; Regis Otaviano França Bezerra; Renata D'Alpino Peixoto; Samuel Aguiar; Ulysses Ribeiro; Tulio Pfiffer; Paulo M Hoff; Anelisa K Coutinho
Journal:  Ecancermedicalscience       Date:  2017-01-26

5.  Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary.

Authors:  Andrew E Hendifar; Robert A Ramirez; Lowell B Anthony; Eric Liu
Journal:  Pancreas       Date:  2019-10       Impact factor: 3.327

Review 6.  Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC.

Authors:  Nasim Vahidfar; Saeed Farzanehfar; Mehrshad Abbasi; Siroos Mirzaei; Ebrahim S Delpassand; Farzad Abbaspour; Yalda Salehi; Hans Jürgen Biersack; Hojjat Ahmadzadehfar
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

7.  Evaluation of Blood Parameters Alteration Following Low-dose Radiation Induced by Myocardial Perfusion Imaging.

Authors:  M S Alavi; M A Okhovat; M Atefi; F Khajeh Rahimi; S Mortazavi; F Ebadi
Journal:  J Biomed Phys Eng       Date:  2018-06-01

8.  Treatment options for PNET liver metastases: a systematic review.

Authors:  Giuseppe Nigri; Niccolò Petrucciani; Tarek Debs; Livia Maria Mangogna; Anna Crovetto; Giovanni Moschetta; Raffaello Persechino; Paolo Aurello; Giovanni Ramacciato
Journal:  World J Surg Oncol       Date:  2018-07-14       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.